Live Coverage from the GU Cancers ...

Check out our coverage of the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA

Darolutamide Improves Metastasis-Free Survival in CRPC

Median metastasis-free survival was longer with darolutamide than with placebo: 40.4 vs 18.4 months.

Adding Docetaxel to ADT Not Beneficial ...

In a study of men with nonmetastatic high-risk prostate cancer who have rising PSA after primary therapy, investigators found no significant difference in PSA progression-free survival.

Improving Dialysis for Undocumented Immigrants

Many are calling for standard dialysis coverage for undocumented immigrants with end-stage renal disease.

Post-RT Time to PSA Nadir Predictive

Men with unfavorable-risk prostate cancer who had a detectable PSA nadir and a time to PSA nadir less than 12 months had a 5-fold increased risk of dying from their disease.

Dialysis Death Risk Bigger Than Cancers'

Compared with patients on maintenance dialysis, men with prostate cancer and women with breast cancer have better unadjusted 5-year survival probabilities.

Enarodustat Effective for Renal Anemia

The medication showed promise as correction and maintenance therapy in a phase 2b trial of non-dialysis CKD patients with anemia.

Email Precautions Can Prevent Breaches

Staff at medical practices should be taught to recognize suspicious email messages

When Patients Refuse Treatment

Find Jobs

Check out Renal & Urology News' job board


Jan-Feb Digital Issue

Sign Up for Free e-newsletters